Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVWF (VONVENDI) in Chinese patients with von Willebrand disease
ChiCTR2500108310Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa in von Willebrand disease (VWD), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs), Incidence of thromboembolic events and severe hypersensitivity reactions and 3 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on ChiCTR2500108310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108310.